Merck & Co., Inc. (MRK) Price History:45.67%(TTM)
The price cagr for Merck & Co., Inc. (MRK) is +45.67% over the latest trailing 12-month period. The comparable SPY value is +20.75%. Year-to-date price return is +11.29%. Price CAGR uses adjusted close price history and excludes dividends.
Current Price
$118.47
$-1.13 (-0.94%)
Previous Close: $119.60
Today's Trading
- Open
- $119.16
- Day High
- $120.04
- Day Low
- $117.26
- Volume
- 6.44M
- Avg Volume
- 9.93M
52-Week Position
86%
of the 52-week price range
- From 52-week high
- -5.33%
- From 52-week low
- +54.54%
52-Week Price Range
52-Week Low
$76.66
Sep 25, 2025
Current Price
$118.47
86% of range
52-Week High
$125.14
Feb 24, 2026
Price Returns by Period
1 Day
-0.94%
7 Days
+3.29%
30 Days
+6.46%
YTD
+11.29%
1 Year
+45.63%
vs 52W High
-5.33%
MRK Price Chart
Long-Term Performance (CAGR)
Price CAGR (3Y)
+2.28%
Price CAGR (5Y)
+9.25%
Total Return CAGR (3Y)
+5.46%
Total Return CAGR (5Y)
+12.73%
CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.
Key Price Statistics
| Current Price | $118.47 |
| Previous Close | $119.60 |
| Day Range | $117.26 - $120.04 |
| 52-Week Range | $76.66 - $125.14 |
| Volume | 6.44M |
| Average Volume | 9.93M |
| Market Cap | $293.02B |
| % from 52W High | -5.33% |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis